SEMA5A and familial pancreatic carcinoma: On the contrary, Sema5A was reported to promote invasion/metastasis in gastric cancer through activation of metalloprotease-9 (MMP-9) and urokinase-type plasminogen activator, and to increase pancreatic cancer metastasis via the Met receptor tyrosine kinase or the MEK/ERK pathway [11–15].